Despite a significant net loss, Allogene Therapeutics Inc (ALLO) advances key trials in large B-cell lymphoma and autoimmune ...

ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

Citizens upgraded Allogene Therapeutics (NASDAQ:ALLO) to Market Perform from Market Underperform on Friday, establishing a $5 ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ...

As Michelle struggles to send a microfilm to England by homing pigeon, Herr Flick captures Yvette and Mimi in order to gain access to the café and search for the Fallen Madonna with the Big Boobies. A ...

Liverpool have been scouring the market for a left-back to replace 31-year-old Scot Andy Robertson with Bournemouth's Hungary defender Milos Kerkez, 21, one of their main targets. Newcastle ...